公司概覽
業務類別 --
業務概覽 PT Kalbe Farma Tbk is engaged in the development, manufacturing, and trading of pharmaceutical products, including human medicines and consumer health products. The company operates four segments: prescription pharmaceuticals, consumer health, Nutritionals, and distribution and logistics. The majority of the company's revenue is derived from the distribution and logistics segments. Its Product and Services are Prescription /Ethicals, Consumer Health, Nutritionals, Distribution & Logistics, Health Services, Medical Devices, and Others.
公司地址 Jalan Let. Jend. Suprapto Kav. 4, Gedung KALBE, Cempaka Putih, P.O. Box 3105, Jakarta, IDN, 10510
電話號碼 +62 2142873888
傳真號碼 +62 214244983
公司網頁 https://www.kalbe.co.id
員工數量 16487
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
沒有相關資料。
 
董事會成員
董事會 職務 更新日期
Mr. Rhenald Kasali Member of the Board of Commissioners 25/04/2025
Ms. Lilis Halim Member of the Board of Commissioners 25/04/2025
Mr. Vidjongtius Vidjongtius President of the Board of Commissioners 25/04/2025
Mr. Ronny Hadiana Member of the Board of Commissioners 25/04/2025
Mr. Santoso Oen Member of the Board of Commissioners 25/04/2025
Mr. Ferdinand Aryanto Member of the Board of Commissioners 25/04/2025
 
所屬ETF (更新日期: 02/05/2026 02:38)
代號 名稱 佔比% 持有日期
JSTCAdasina Social Justice All Cp Glbl ETF<0.000001%28/11/2025
LDEMiShares® ESG MSCI EM Leaders ETF<0.000001%06/03/2026
NUEMNuveen ESG Emerging Markets Equity ETF<0.000001%25/11/2025
PPEMPutnam PanAgora ESG Emerg Mkts Eq ETF<0.000001%03/11/2025
SEEMSEI Select Emerging Markets Equity ETF<0.000001%20/10/2025
XCWisdomTree True Emerging Markets ETF<0.000001%21/04/2026
XSOEWisdomTree EmMkts ex-Stt-Ownd EntrprsETF<0.000001%16/10/2025
  1    2    3   4  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.